|158.85||+3.17||+2.04%||Vol 1.73M||1Y Perf -30.25%|
|Nov 29th, 2023 16:00 DELAYED|
|- -%||- -|
|Target Price||261.11||Analyst Rating||Moderate Buy 1.79|
|Potential %||64.38||Finscreener Ranking||★★+ 48.20|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★+ 52.31|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★+ 63.85|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||★+ 37.07|
|Price Range Ratio 52W %||23.91||Earnings Rating||Buy|
|Market Cap||23.37B||Earnings Date||26th Oct 2023|
Today's Price Range
5 Year PE Ratio Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||1.63|
|EPS Growth Next 5 Years %||8.00|
|Avg. Weekly Volume||639.28K|
|Avg. Monthly Volume||1.20M|
|Avg. Quarterly Volume||1.57M|
ResMed Inc. (NYSE: RMD) stock closed at 158.85 per share at the end of the most recent trading day (a 2.04% change compared to the prior day closing price) with a volume of 1.73M shares and market capitalization of 23.37B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 7970 people. ResMed Inc. CEO is Michael J. Farrell.
The one-year performance of ResMed Inc. stock is -30.25%, while year-to-date (YTD) performance is -23.68%. RMD stock has a five-year performance of 42.1%. Its 52-week range is between 132.24 and 243.52, which gives RMD stock a 52-week price range ratio of 23.91%
ResMed Inc. currently has a PE ratio of 39.00, a price-to-book (PB) ratio of 8.91, a price-to-sale (PS) ratio of 11.25, a price to cashflow ratio of 66.60, a PEG ratio of 4.88, a ROA of 16.80%, a ROC of 18.86% and a ROE of 25.73%. The company’s profit margin is 21.47%, its EBITDA margin is 33.20%, and its revenue ttm is $2.73 Billion , which makes it $18.63 revenue per share.
Of the last four earnings reports from ResMed Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $1.63 for the next earnings report. ResMed Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for ResMed Inc. is Moderate Buy (1.79), with a target price of $261.11, which is +64.38% compared to the current price. The earnings rating for ResMed Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
ResMed Inc. has a dividend yield of 0.84% with a dividend per share of $1.76 and a payout ratio of 48.00%.
ResMed Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 14.75, ATR14 : 4.55, CCI20 : 194.70, Chaikin Money Flow : 0.02, MACD : 2.60, Money Flow Index : 55.32, ROC : 10.76, RSI : 64.39, STOCH (14,3) : 77.46, STOCH RSI : 1.00, UO : 55.01, Williams %R : -22.54), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of ResMed Inc. in the last 12-months were: Brett A. Sandercock (Sold 14 000 shares of value $3 012 196 ), Brett Sandercock (Sold 30 000 shares of value $6 738 579 ), David B. Pendarvis (Sold 10 500 shares of value $2 335 095 ), Kaushik Ghoshal (Sold 4 500 shares of value $1 019 650 ), Michael J. Farrell (Sold 0 shares of value $-1 638 940 ), Michael J. Farrell (Sold 28 375 shares of value $6 163 114 ), Rider Michael J (Sold 25 shares of value $5 603 ), Robert Andrew Douglas (Sold 6 000 shares of value $1 297 080 )
Fri, 27 Oct 2023 12:50 GMT Analysts Conflicted on These Healthcare Names: Resmed (RMD) and MiMedx Group (MDXG)- TipRanks. All rights reserved.
Mon, 09 Oct 2023 09:20 GMT Analysts Top Healthcare Picks: Resmed (RMD), Bristol-Myers Squibb (BMY)- TipRanks. All rights reserved.
Wed, 27 Sep 2023 13:55 GMT Early notable gainers among liquid option names on September 27th- TipRanks. All rights reserved.
Tue, 26 Sep 2023 13:55 GMT Early notable gainers among liquid option names on September 26th- TipRanks. All rights reserved.
Tue, 15 Aug 2023 13:55 GMT Early notable gainers among liquid option names on August 15th- TipRanks. All rights reserved.
Wed, 19 Jul 2023 09:02 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) and Zur Rose Group AG (Six Swiss: CH:DOCM)- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.